Lacosamid Biomo

Lacosamide, the active ingredient in Lacosamid Biomo, is a sodium channel blocker presented as an oral formulation for oral use. It is indicated for the treatment of partial‑onset seizures and other epilepsy subtypes in adults and children.

GNH USA supplies Lacosamid Biomo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution. The company ensures product integrity through rigorous quality control and supports regulatory compliance for importers.

Lacosamide is used in the management of seizure disorders that involve abnormal neuronal firing.

- Partial‑onset seizures: reduces the frequency of focal seizures when added to existing antiepileptic therapy. - Adjunct therapy in epilepsy: contributes to overall seizure control in patients whose seizures are not fully managed by other medications. - Secondary generalized seizures: helps prevent the spread of focal seizures to bilateral tonic‑clonic seizures. - Lacosamide in refractory epilepsy: offers an alternative mechanism for patients resistant to other sodium channel blockers.

Lacosamide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of lightheadedness or imbalance. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Cardiac arrhythmias (PR interval prolongation): may cause slowed heart conduction. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): rare but potentially life‑threatening rash. - Suicidal thoughts or behavior: emergence of depressive symptoms or self‑harm ideation.

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dosing and monitor renal function. - Hepatic dysfunction: use with caution and assess liver enzymes. - Cardiac conduction abnormalities: obtain baseline ECG and monitor PR interval. - Concomitant CNS depressants: observe for enhanced sedation or dizziness. - Pregnancy and lactation: evaluate risk‑benefit, limited data available. - Store at ambient temperature below 25°C: keep in original container, protect from moisture.

Lacosamide can interact with other medicines, influencing its plasma levels or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce Lacosamide concentrations. - Concomitant drugs that prolong PR interval (e.g., certain antiarrhythmics): increase risk of cardiac conduction delay.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, lamotrigine): may require dose adjustments. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Diuretics causing electrolyte imbalance: monitor electrolytes as they can affect cardiac safety.